Tag: precision medicine

This Scientist Is Auctioning Off His DNA and Says Yours is Valuable Too

George Church’s genes are making history again. The Harvard geneticist was one of the first people to ever have his genome sequenced, and now he...

FDA OKs First ‘Targeted Treatment’ for Rare DMD Mutation

The US Food and Drug Administration (FDA) has approved the antisense oligonucleotide casimersen (Amondys 45, Sarepta Therapeutics) injection for the treatment of patients with Duchenne...

Why genomic pioneer Lee Hood hopes the covid-19 pandemic will make precision medicine based on personalized patient data a reality

Davis believes the key to understanding why covid affects people in such varied ways is to identify the differences between the immune systems of those...

CAR T-cell Products Shine, Reveal New Insights

Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas compares favorably with experience in commercial and trial settings and provides new...

Differences in Right vs Left Colon in Black vs White Individuals

The right colon appears to age faster in Black people than in White people, perhaps explaining the higher prevalence of right-side colon cancer among Black...

First CAR T-cell Tx for Mantle Cell Lymphoma Fills Unmet Need

The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus)...

Charting of the Human Genome, 20 Years Later

Twenty years ago, President Bill Clinton announced completion of what was arguably one of the greatest advances of the modern era: the first draft sequence...

Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma

For patients with heavily-pretreated multiple myeloma, the early and deep responses seen with the novel chimeric antigen receptor T-cell (CAR T-cell) construct ciltacabtagene autoleucel (cilta-cel)...

Mitotic Rate Makes Comeback as Melanoma Prognosticator

Mitotic rate, properly applied, has a prognostic impact in melanoma comparable to that of lesional ulceration, Mohammed Kashani-Sabet, MD, reported at a virtual forum on...

‘Impressive’ Outcomes Sans Chemo in Poor-Prognosis ALL

The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival

A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma

The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to brexucabtagene autoleucel (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for...

CDER Chief Reflects on Advances in Rare Diseases

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Dr Janet Woodcock Since joining the Food and Drug Administration in...

New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor

The investigational kinase inhibitor ipatasertib (Roche), which targets a key cancer metabolic pathway, has shown promise when used in combination with abiraterone (Zytiga) in the...

Readers Predict Biggest Medical Breakthroughs by 2045

When Medscape’s readers were asked to predict medical breakthroughs in the next quarter century, the most common responses zeroed in on the human genome. Altering...

The Earlier the Better for Colchicine Post-MI: COLCOT

The earlier the anti-inflammatory drug colchicine is initiated after a myocardial infarction (MI) the greater the benefit, a new COLCOT analysis suggests. The parent trial...

Physicians, Patients Need to Know Limits of DNA Privacy Law

Because of the role genetic testing now plays in the management of cancer, and in the identification of risk for the disease, physicians should make...

COVID-19 Daily: Male Vulnerability, Semen Study

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Here are the coronavirus stories Medscape’s editors around the globe think...

FDA Approves First Targeted Drug for Bile Duct Cancer

The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer...